Home » Stocks » Greenwich LifeSciences

Greenwich LifeSciences, Inc. (GLSI)

Stock Price: $4.31 USD -0.44 (-9.26%)
Updated Oct 21, 2020 9:54 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 42.87M
Revenue (ttm) n/a
Net Income (ttm) -3.52M
Shares Out 11.95M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $4.31
Previous Close $4.75
Change ($) -0.44
Change (%) -9.26%
Day's Open 4.70
Day's Range 4.31 - 4.70
Day's Volume 137
52-Week Range 4.07 - 5.75

More Stats

Market Cap 42.87M
Enterprise Value 43.50M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 11.95M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.29
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3,201
Short Ratio 0.02
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -3.52M
Free Cash Flow n/a
Net Cash -628,319
Net Cash / Share -0.06
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-3.43-1.69
Net Income-3.43-1.69
Shares Outstanding2.260.20
Earnings Per Share-1.52-8.32
Operating Cash Flow-0.29-0.11
Free Cash Flow-0.29-0.11
Cash & Equivalents0.010.09
Total Debt0.640.42
Net Cash / Debt-0.63-0.34
Book Value-1.35-10.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Greenwich LifeSciences, Inc.
Country United States
Employees 3
CEO Snehal Patel

Stock Information

Ticker Symbol GLSI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GLSI
IPO Date September 25, 2020


Greenwich LifeSciences, a clinical stage biopharmaceutical company, focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in 2006 and is based in Stafford, Texas.